about
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureNelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precurInsertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitnessUnderstanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.HIV-1 antiretroviral drug therapy.Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibilityColinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencingThe human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted virusesReplication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection.Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.
P2860
Q28478779-F60EBD57-F619-49A9-BCC0-817EFF8D2A42Q34344036-C5006B8F-D48A-480A-AF14-11F37C2E0F24Q34348774-7E7ECC32-10A6-45F7-8078-715419607F33Q34651403-07EF807F-9431-4DE9-A1BF-BAB305B485B9Q35842525-AEF142AC-BDDD-458C-9A32-EDD7DD5C338EQ35853012-4E367D48-0342-4E1A-8A33-863D5FA5179FQ36492224-725E42A6-88FD-4535-8298-AE7E4EB89C5FQ36950126-8610ED9D-763F-427C-AA95-06A0EE52FBEBQ36974671-E013C8FB-A672-497D-AE86-E4CE0F774A71Q37483095-CEBCE1BB-919C-49D7-ADD8-8267B469F2E5Q39996438-4FF011FA-26EA-483F-AE85-ACD17F9ED567Q42686885-B8DAA527-797F-4F3A-8371-406B5BA78039Q42931192-A942274E-8AD6-42EB-9E94-78F9288F5BC4
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
HIV drug resistance and viral fitness.
@ast
HIV drug resistance and viral fitness.
@en
HIV drug resistance and viral fitness.
@nl
type
label
HIV drug resistance and viral fitness.
@ast
HIV drug resistance and viral fitness.
@en
HIV drug resistance and viral fitness.
@nl
prefLabel
HIV drug resistance and viral fitness.
@ast
HIV drug resistance and viral fitness.
@en
HIV drug resistance and viral fitness.
@nl
P1476
HIV drug resistance and viral fitness
@en
P356
10.1016/S1054-3589(00)49023-X
P577
2000-01-01T00:00:00Z